Loading...
XNASSIGA
Market cap453mUSD
Jan 15, Last price  
6.35USD
1D
0.32%
1Q
-10.18%
Jan 2017
120.49%
Name

SIGA Technologies Inc

Chart & Performance

D1W1MN
XNAS:SIGA chart
P/E
6.66
P/S
3.24
EPS
0.95
Div Yield, %
7.09%
Shrs. gr., 5y
-2.82%
Rev. gr., 5y
-21.75%
Revenues
140m
+26.31%
1,839,1828,476,7417,257,5326,698,7178,065,61813,811,85819,215,83712,725,7928,970,8355,519,3003,139,8358,175,87814,987,62812,268,960477,053,78226,742,085124,959,304133,670,454110,775,610139,917,220
Net income
68m
+100.76%
-9,373,319-2,287,550-9,898,708-5,638,557-8,599,377-17,617,939-28,195,33913,594,176-14,528,153-17,177,333-265,463,138-39,451,324-39,697,960-36,235,484421,807,828-7,241,14756,342,01069,450,76633,904,80668,068,826
CFO
95m
+127.82%
-4,890,058-1,392,451-4,438,005-5,447,833-7,197,886-8,470,829-10,825,38425,574,036-20,222,82658,436,50214,176,52011,109,383-115,590,781-8,158,29868,871,323-18,204,30371,519,22811,494,63641,611,06294,799,331
Dividend
Mar 25, 20240.6 USD/sh
Earnings
Mar 10, 2025

Profile

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
URL
https://www.siga.com/
IPO date
Sep 09, 1997
Employees
39
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
139,917
26.31%
110,776
-17.13%
Cost of revenue
34,253
57,072
Unusual Expense (Income)
NOPBT
105,664
53,703
NOPBT Margin
75.52%
48.48%
Operating Taxes
19,708
10,228
Tax Rate
18.65%
19.05%
NOPAT
85,956
43,475
Net income
68,069
100.76%
33,905
-51.18%
Dividends
(32,135)
(32,940)
Dividend yield
8.01%
6.09%
Proceeds from repurchase of equity
(11,073)
(13,006)
BB yield
2.76%
2.40%
Debt
Debt current
564
528
Long-term debt
900
528
Deferred revenue
Other long-term liabilities
3,376
2,822
Net debt
(148,682)
(97,734)
Cash flow
Cash from operating activities
94,799
41,611
CAPEX
(22)
Cash from investing activities
(22)
Cash from financing activities
(43,422)
(45,959)
FCF
95,497
53,580
Balance
Cash
150,146
98,791
Long term investments
Excess cash
143,150
93,252
Stockholders' equity
(38,937)
(63,798)
Invested Capital
239,736
235,998
ROIC
36.14%
19.21%
ROCE
52.62%
31.09%
EV
Common stock shares outstanding
71,679
73,547
Price
5.60
-23.91%
7.36
-2.13%
Market cap
401,404
-25.84%
541,302
-5.79%
EV
252,722
443,568
EBITDA
106,202
54,221
EV/EBITDA
2.38
8.18
Interest
918
Interest/NOPBT
1.71%